Xencor (XNCR) Expected to Announce Quarterly Earnings on Monday

Xencor (NASDAQ:XNCR) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Monday, August 4th. Analysts expect the company to announce earnings of ($0.78) per share and revenue of $22.59 million for the quarter.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative net margin of 181.17% and a negative return on equity of 31.94%. The business had revenue of $32.73 million for the quarter, compared to the consensus estimate of $23.44 million. During the same quarter last year, the firm earned ($1.11) EPS. The company’s revenue for the quarter was up 104.6% on a year-over-year basis. On average, analysts expect Xencor to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Xencor Trading Down 4.1%

NASDAQ:XNCR opened at $7.98 on Friday. Xencor has a fifty-two week low of $7.16 and a fifty-two week high of $27.24. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.89 and a quick ratio of 5.89. The stock has a market capitalization of $567.94 million, a PE ratio of -2.61 and a beta of 0.89. The business’s 50-day simple moving average is $8.67 and its 200-day simple moving average is $11.50.

Insider Buying and Selling at Xencor

In other Xencor news, Director Ellen Feigal sold 2,993 shares of the business’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the sale, the director owned 19,183 shares in the company, valued at approximately $176,867.26. The trade was a 13.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kurt A. Gustafson sold 2,993 shares of the company’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the sale, the director owned 20,183 shares in the company, valued at approximately $186,087.26. This represents a 12.91% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,194 shares of company stock worth $103,209. Corporate insiders own 4.76% of the company’s stock.

Institutional Investors Weigh In On Xencor

Institutional investors and hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC bought a new stake in shares of Xencor during the 1st quarter worth approximately $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Xencor by 9.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company’s stock worth $471,000 after purchasing an additional 3,692 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Xencor by 89.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company’s stock worth $7,732,000 after purchasing an additional 344,088 shares in the last quarter.

Wall Street Analyst Weigh In

XNCR has been the topic of several recent analyst reports. Barclays cut their price objective on Xencor from $22.00 to $6.00 and set an “underweight” rating on the stock in a report on Thursday, May 8th. Wedbush reiterated an “outperform” rating and set a $31.00 price objective on shares of Xencor in a report on Wednesday, April 30th. Finally, William Blair began coverage on Xencor in a research note on Monday, April 21st. They issued an “outperform” rating on the stock. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Xencor has an average rating of “Moderate Buy” and an average price target of $28.00.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.